Home › Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease
 

Keywords :   


Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease

2015-09-30 08:48:02| drugdiscoveryonline News Articles

Intersect ENT, Inc., a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, recently announced that the company has submitted a supplemental premarket approval (PMA-s) submission to the U.S

Tags: mini expanded disease patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
More »